MCP
EW icon

Meridiem Capital Partners’s Edwards Lifesciences EW Stock Holding History

Meridiem Capital Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.7M Buy
233,189
+118,424
+103% +$9.76M 1.22% 32
2025
Q4 		$9.78M Buy
+114,765
New +$9.42M 0.59% 54
2025
Q2 		– Sell
-372,822
Closed -$27M – 80
2025
Q1 		$27M Buy
372,822
+329,979
+770% +$23.6M 2.82% 12
2024
Q4 		$3.17M Buy
+42,843
New +$3M 0.28% 60

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Meridiem Capital Partners's EW Position: Q1 2026 in Review

Meridiem Capital Partners increased its Edwards Lifesciences (EW) stake by 103% in Q1 2026, buying an estimated $9.76M and bringing the position to 233,189 shares worth $18.7M. The position accounts for 1.22% of the portfolio, ranked #32.

Meridiem Capital Partners first reported a position in EW in Q4 2024 and has held it in 4 quarters since. The position peaked at $27M in Q1 2025. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Meridiem Capital Partners held 233,189 shares of Edwards Lifesciences worth $18.7M as of Q1 2026.
  • Meridiem Capital Partners bought 118,424 Edwards Lifesciences shares in Q1 2026, an estimated $9.76M.
  • Edwards Lifesciences made up 1.22% of Meridiem Capital Partners's portfolio in Q1 2026, its #32 holding.
  • Meridiem Capital Partners first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 4 quarters since.
  • Meridiem Capital Partners's Edwards Lifesciences position peaked at $27M in Q1 2025.
  • 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Meridiem Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.